Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd has appointed M/s. D Maurya & Associates as its Secretarial Auditor for the financial year 2026-27, following the recommendation of the Audit Committee and approval by the Board of Directors on May 21, 2026. The appointment complies with Regulation 30 of the SEBI Listing Regulations. M/s. D Maurya & Associates is a Mumbai-based firm established in 2010, with Dhirendra Maurya as its proprietor.

Ganga Pharmaceuticals Ltd has appointed M/s. Deepak Jedhe & Co, Chartered Accountants, as its Internal Auditor for the financial year 2026-27. The appointment was approved by the Board of Directors on May 21, 2026, based on the recommendation of the Audit Committee. Deepak Jedhe & Co is a Chartered Accountancy firm founded in 2015, offering assurance, taxation, and advisory services.

Ganga Pharmaceuticals Ltd. announced that its Board of Directors approved the audited financial results for the half year and financial year ended March 31, 2026, following a meeting held on May 21, 2026. The statutory auditors have issued an audit report with an unmodified opinion on these results. The financial results and auditor's report are available on the company's website.

Ganga Pharmaceuticals Ltd's Board of Directors approved the audited financial results for the half year and financial year ended March 31, 2026, during its meeting held on May 21, 2026. The statutory auditors, Banka & Banka, issued an audit report with an unmodified opinion on the financial results. The meeting commenced at 3:30 p.m. and concluded at 4:00 p.m. The results are available on the company's website.

Ganga Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the Audited Financial Results for the half year and financial year ended March 31, 2026. In compliance with SEBI regulations, the trading window for dealing in the company's securities has been closed from April 1, 2026, and will reopen 48 hours after the results are declared.

Ganga Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons from Wednesday, April 01, 2026. This closure is in accordance with the company's Code of Conduct for prevention of Insider Trading. The closure is in connection with the declaration of Audited Financial Results of the Company for the six months and financial year ending on March 31, 2026. The trading window will open 48 hours after the financial results are declared to the Stock Exchange.

Ganga Pharmaceuticals Ltd. has announced the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director for a further period of three years, effective from April 01, 2026. The re-appointment is subject to the approval of the Members of the Company. Mr. Sharma, with over 35 years of experience in Business and Pharma Industry, is not debarred from holding the office of Director by virtue of any SEBI order or order of any other such Authority.

Ganga Pharmaceuticals Ltd has announced the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director for a further period of three years effective from April 01, 2026. The re-appointment is subject to the approval of the Members of the Company. Mr. Sharma, with over 35 years of experience in Business and Pharma Industry, is not liable to retire by rotation. His spouse, Mrs. Srijna Sharma, is a Whole-time Director of the Company.

Ganga Pharmaceuticals Ltd has reported no deviation or variation in the utilization of funds raised through equity shares upon Convertible Warrants under Preferential Issue on July 17, 2025. The funds were raised for funding capital expenditure requirements, augmenting working capital needs, and general corporate purposes. As of September 30, 2025, there is an unutilized amount of Rs 53,48,145/-.

Ganga Pharmaceuticals Ltd. has announced its un-audited financial results for the half year ended on September 30, 2025. The Board of Directors approved the results in a meeting held on November 07, 2025. The company's revenue from operations stands at INR 136.65 crores, with a net profit of INR 14.80 crores. The total income and total expenses for the period are INR 263.74 crores and INR 248.94 crores, respectively.